Skip to main content
Venus Medtech (Hangzhou) Inc. logo

Venus Medtech (Hangzhou) Inc. — Investor Relations & Filings

Ticker · 2500 ISIN · CNE100003PJ8 HKEX Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2026-01-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2500

About Venus Medtech (Hangzhou) Inc.

http://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. is an innovation-driven medical device company specializing in the research, development, manufacturing, and commercialization of transcatheter solutions for structural heart diseases. The company focuses on bioprosthetic heart valves, establishing a comprehensive pipeline that addresses aortic, pulmonary, mitral, and tricuspid valve diseases. Its product portfolio includes transcatheter aortic valve replacement (TAVR) solutions, and it is committed to addressing unmet demand in TPVR and TMVR. The company also develops solutions for hypertension, such as renal artery denervation ablation, and related surgical accessory products. Its products are commercialized globally, reaching over 60 countries and regions across Asia, Europe, and the Americas.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2025
Regulatory Filings Classification · 100% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in their securities, share capital, and treasury shares. It does not fit into categories like Annual Reports, Earnings Releases, or M&A activity, but rather serves as a recurring regulatory disclosure of share capital changes. Therefore, it is classified as a Regulatory Filing (RNS).
2026-01-06 English
DISCLOSEABLE TRANSACTION IN RELATION TO DISPOSAL OF SHARES OF AN INVESTEE COMPANY
M&A Activity Classification · 100% confidence The document is an official announcement from Venus Medtech (Hangzhou) Inc. regarding a 'Disclosable Transaction' involving the disposal of shares in an investee company. It details the Share Transfer Agreement, consideration, listing rule implications, and financial effects of the transaction. This fits the definition of M&A activity (TAR) as it concerns the divestment/disposal of assets/investments, which is a standard component of M&A reporting under stock exchange listing rules.
2025-12-29 English
VOLUNTARY ANNOUNCEMENT SUBMISSION OF CE MDR MARKING APPLICATION FOR THE CARDIOVALVE TRICUSPID VALVE REPLACEMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement issued by Venus Medtech regarding the submission of a CE MDR marking application for a specific medical product (Cardiovalve). It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a general regulatory announcement regarding business development that does not fall into specific categories like M&A or share dealings, it is classified as a general regulatory filing.
2025-12-24 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Earnings Release' or 'Annual Report' but is a mandatory regulatory filing for ongoing compliance, thus falling under the 'Regulatory Filings' category.
2025-12-03 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING' and details the voting outcomes for a specific resolution proposed at an EGM held on November 28, 2025. It includes the number of shares voted for, against, and abstained, and confirms the resolution was passed. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-11-28 English
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE
Regulatory Filings Classification · 95% confidence The document is a 'Voluntary Announcement' issued by Venus Medtech (Hangzhou) Inc. regarding clinical trial results for their Cardiovalve product. It is not a formal financial report (10-K, IR), nor is it a transcript or proxy statement. It serves as a business update to shareholders and investors, which falls under the category of general regulatory announcements for companies listed on the Hong Kong Stock Exchange.
2025-11-19 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.